drugset / Trial / NCT00996931
Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if lenalidomide (Revlimid®)reduces proinflammatory cytokines including TNF-alpha and may actually alter the clinical course of autism for some children.
Timeline
- Start
- 2009-02
- Primary completion
- 2009-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 2.5 mg | Oral |